Clinical Trial Detail

NCT ID NCT04128696
Title Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

hypopharynx cancer

oral cavity cancer

laryngeal squamous cell carcinoma

oropharynx cancer

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

GSK3359609 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.